Purpose: 

To determine the effectiveness of retrobulbar liposomal bupivacaine for controlling postoperative pain following evisceration, compared with 0.75% bupivacaine.

Methods: 

Randomized controlled trial, in which the postoperative pain scores from 24 patients who had retrobulbar liposomal bupivacaine after an evisceration were compared with the pain scores from 24 patients eviscerated using 0.75% bupivacaine.

Results: 

Patients who received liposomal bupivacaine reported significantly less pain at 24 hours (2.0 out of 10, p = 0.01) and 48 hours (2.2 out of 10, p = 0.01) after surgery than patients who received 0.75% bupivacaine (5.7, and 5.0, respectively). The postoperative pain scores at 1 hour and at 7 days did not significantly differ between the 2 groups. Significantly, fewer patients who received liposomal bupivacaine (0%) than patients who received 0.75% bupivacaine (16.7%) returned emergently during the postoperative period for uncontrolled pain (p ≤ 0.001).

Conclusions: 

Retrobulbar liposomal bupivacaine is more effective than 0.75% bupivacaine for controlling pain during the first 2 days after evisceration and should be considered for patients undergoing this procedure.

中文翻译：

---

脂质体布比卡因混悬液用于控制眼内取出手术后的疼痛

目的： 

与 0.75% 布比卡因相比，确定球后脂质体布比卡因控制内脏术后疼痛的有效性。

方法： 

随机对照试验，将 24 名在取出内脏后接受球后脂质体布比卡因的患者的术后疼痛评分与 24 名使用 0.75% 布比卡因取出内脏的患者的术后疼痛评分进行比较。

结果： 

接受脂质体布比卡因的患者报告术后24 小时（10 分之 2.0，p = 0.01）和 48 小时（10 分之 2.2，p = 0.01）的疼痛明显少于接受 0.75% 布比卡因的患者（5.7 和 5.0，分别）。两组术后1小时和7天的疼痛评分没有显着差异。值得注意的是，与接受 0.75% 布比卡因 (16.7%) 的患者相比，接受脂质体布比卡因 (0%) 的患者在术后期间因不受控制的疼痛而紧急返回的患者较少 (p ≤ 0.001 )。

结论： 

球后脂质体布比卡因对于控制内脏取出后前 2 天内的疼痛比 0.75% 布比卡因更有效，接受此手术的患者应考虑使用。